Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer

NCT02116894

Last updated date
Study Location
Duke Cancer Center, Duke University Medical Center
Durham, North Carolina, 27710, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Colorectal Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Histologically and/or cytologically confirmed and radiographically evaluable refractory metastatic colorectal adenocarcinoma for which regorafenib would be considered a therapeutic option.

2. Disease must be measurable by RECIST 1.1 criteria (see Appendix 1).

3. Age ≥ 18 years.

4. ECOG 0 or 1.

5. Life expectancy of at least 3 months.

6. Adequate bone marrow function as shown by:

1. ANC ≥ 1.5 x 109

2. Platelets ≥ 100 x 109/L

3. Hemoglobin ≥ 9 g/dL; Erythropoietin and transfusion support is permitted provided treatments are not required more than every 8 weeks. Hemoglobin must be stable above or equal to 9 g/dL for at least 2 weeks prior to day 1of study drug without blood transfusion to maintain hemoglobin level.

7. Adequate liver function as shown by:

1. serum bilirubin ≤ 1.5x ULN

2. PT/PTT/INR ≤ 1.5x ULN

3. ALT and AST ≤ 2.5x ULN

8. Adequate renal function: creatinine clearance (estimated) ≥ 50 cc/min by Cockroft Gault or 24 hour urine (see Appendix 6).

9. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days from day 1 of study drug; both men and women must be willing to use two methods of contraception, one of them being a barrier method during the study and for 6 months after last study drug administration.

10. Signed informed consent.

11. Presence of an archived tumor sample (no size requirements).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Prior regorafenib use with disease progression (expanded cohort only).


2. Prior failure to tolerate regorafenib at 120 mg/day.


3. Patients currently receiving anticancer therapies or who have received anticancer
therapies within 28 days from day 1 of study drug (including investigational agents,
chemotherapy, radiation therapy, antibody based therapy, etc.)


4. Patients who:


1. Have had a major surgery or significant traumatic injury within 4 weeks from day
1 of study drug,


2. Have not recovered from the side effects of any major surgery (defined as
requiring general anesthesia) or


3. Are anticipated to require major surgery during the course of the study.


5. Patients who have exhibited hypersensitivity reactions to regorafenib and/or a
structural compound, biological agent, or formulation (eg sorafenib).


6. Grade 3-4 AE associated with prior anti-VEGF therapy. Grade 3 hypertension that was
readily managed will be permitted.


7. History of grade 3 or higher hypersensitivity reactions/anaphylaxis attributed to
humanized and/or chimeric monoclonal antibodies or other such proteins.
Hypersensitivity reactions that are clearly related to cetuximab may be permitted at
the discretion of the principal investigator.


8. Patients receiving chronic, systemic treatment with corticosteroids or another
immunosuppressive agent with the following exceptions:


1. Intermittent steroids (not to exceed 4 mg every day) may be used on an as-needed
basis (e.g. treatment for chemotherapy-related nausea, anorexia and fatigue.)


2. Patients on physiologic replacement doses of steroids due to adrenal
insufficiency for any reason may remain on these medications.


3. Topical, inhaled or intra-articular corticosteroids


9. Active brain or leptomeningeal metastases, including patients who continue to require
glucocorticoids for brain or leptomeningeal metastases. Treated, asymptomatic
metastases are permitted provided the patient has been off steroids for at least 1
month prior to day 1 of study drug.


10. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires
supplementary oxygen, symptoms due to hypoxemia or O2 saturation <90% by pulse
oximetry after a 2 minute walk or in the opinion of the investigator any physiological
state likely to cause systemic or regional hypoxemia.


11. Presence of poorly controlled atrial fibrillation (ventricular heart rate >100 bpm)


12. Previous history of CVA, TIA, angina pectoris, acute MI or history of recent
re-perfusion procedures (e.g. PTCA), pulmonary embolus or untreated deep vein
thrombosis (DVT) within 6 months from day 1 of study drug. NOTE: Subjects with recent
DVT who have been therapeutically anti-coagulated for at least 6 weeks are eligible.


13. Known significant or active CAD or PVD or CVD defined as abnormal stress test,
symptoms, or requiring medication for the prevention of symptoms.


14. Congestive heart failure (New York Heart Association (NYHA classification, see
Appendix 4 functional classification III-IV).


15. Proteinuria at screening demonstrated by urine analysis (UA) > 1+ and 24 hour urine
protein ≥ 1 gram/24 hours.


16. Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation in the study as so judged by the
treating physician. Examples include but are not limited to:


1. Severely impaired lung function (e.g. use of home O2, history of Idiopathic Lung
Disease (ILD), any evidence of ILD on scan.


2. Active (acute or chronic) severe infections requiring treatment with I.V.
antibiotics.


3. Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
hepatitis.


4. Poorly controlled hypertension [defined as systolic blood pressure (SBP of >140
mmHg or diastolic blood pressure (DBP) of >90 mmHg] NOTE: Initiation or
adjustment of antihypertensive medication(s) is permitted prior to study entry.
Following antihypertensive medication initiation or adjustment, blood pressure
(BP) must be re-assessed three times at approximately 2-minute intervals. At
least 24 hours must have elapsed between anti-hypertensive medication initiation
or adjustment and BP measurement. These three values should be averaged to obtain
the mean diastolic blood pressure and the mean systolic blood pressure. The mean
SBP/DBP ratio must be <140/90 mmHg in order for a subject to be eligible for the
study.


17. Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of oral medications (e.g., ulcerative disease,
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
resection).


18. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or
recent peripheral arterial thrombosis) within 6 months prior to day 1 of study drug


19. History of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per
episode) or other significant spontaneous bleeding event within 1 month prior to day 1
of study drug or at any time on a prior VEGF inhibitor.


20. History of abdominal fistula or gastrointestinal perforation at any point within 6
months prior to day 1 of study drug, unless surgically repaired.


21. Active peptic ulcer disease, inflammatory bowel disease (e.g. ulcerative colitis,
Crohn's disease), or other gastrointestinal conditions with increased risk of
perforation or gastrointestinal bleeding.


22. Use or need for full dose anticoagulation other than low molecular weight heparin and
Factor Xa inhibitors (e.g. Lovenox, Fondaparinux) and no other bleeding risk.


23. Serious, non-healing wound, active ulcer, or untreated bone fracture as judged by
treating physician.


24. Active bleeding diathesis.


25. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that
increase the risk of pulmonary hemorrhage.


26. Known history of HIV or Hepatitis B or C seropositivity.


27. Female patients who are pregnant or breast feeding, or adults of reproductive
potential who are not using effective birth control methods. Two acceptable forms of
contraceptives must be continued throughout the trial by either sex and for 2 months
(60 days) following last dose of either drug. Hormonal contraceptives are not
acceptable as a sole method of contraception. (Women of childbearing potential must
have a negative serum pregnancy test within 7 days prior to day 1 of study drug).


28. Concomitant use of CYP3A4 strong inducers and strong inhibitors. (See Appendix 7).


29. Corrected QTc interval > 500 msec. If QTc interval is > 500 msec, then 2 additional
ECGs should be obtained over a brief period of time (e.g., within 15-20 minutes) to
confirm the abnormality. The average QTc interval will be determined from the 3 ECG
tracings by manual evaluation and will be used to determine if the subject will be
excluded from the study. The same method of QTc determination must be used throughout
the subject's participation in the trial.


30. History of Osler-Weber-Rendu syndrome or Hereditary Hemorrhagic Telangiectasia


31. Patients unwilling to or unable to comply with the protocol.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Colorectal CancerPhase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
NCT00522665
  1. Chicago, Illinois
  2. Galesburg, Illinois
  3. Bloomington, Indiana
  4. Evansville, Indiana
  5. Indianapolis, Indiana
  6. Indianapolis, Indiana
  7. Indianapolis, Indiana
  8. Indianapolis, Indiana
  9. Lafayette, Indiana
  10. Lafayette, Indiana
  11. Munster, Indiana
  12. New Albany, Indiana
  13. South Bend, Indiana
  14. St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal CancerA Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
NCT01490866
  1. Jonesboro, Arkansas
  2. Fort Myers, Florida
  3. Pensacola, Florida
  4. Saint Petersburg, Florida
  5. Gainesville, Georgia
  6. Newburgh, Indiana
  7. Terre Haute, Indiana
  8. Grand Rapids, Michigan
  9. Omaha, Nebraska
  10. Summit, New Jersey
  11. Nashville, Tennessee
  12. Dallas, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal CancerFOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
NCT00323011
  1. Los Angeles, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Official Title  ICMJE Phase Ib Study of the Combination Regorafenib With PF-03446962 in Patients With Refractory Metastatic Colorectal Cancer (REGAL-1 Trial)
Brief Summary The primary objective of this open-label phase Ib trial is to determine the maximum tolerated dose and the recommended phase II dose for the combination of PF-03446962 plus regorafenib in patients with metastatic colorectal cancer. The secondary objectives are to describe the safety and tolerablility, and to describe the clinical activity of PF-03446962 plus regorafenib in terms of response rate and progression free survival
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer
Intervention  ICMJE
  • Biological: PF-03446962
    PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
  • Drug: Regorafenib
    We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
Study Arms  ICMJE Experimental: PF-03446962 plus regorafenib
Interventions:
  • Biological: PF-03446962
  • Drug: Regorafenib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 20, 2016)
11
Original Estimated Enrollment  ICMJE
 (submitted: April 15, 2014)
24
Actual Study Completion Date  ICMJE May 2016
Actual Primary Completion Date February 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically and/or cytologically confirmed and radiographically evaluable refractory metastatic colorectal adenocarcinoma for which regorafenib would be considered a therapeutic option.
  2. Disease must be measurable by RECIST 1.1 criteria (see Appendix 1).
  3. Age ? 18 years.
  4. ECOG 0 or 1.
  5. Life expectancy of at least 3 months.
  6. Adequate bone marrow function as shown by:

    1. ANC ? 1.5 x 109
    2. Platelets ? 100 x 109/L
    3. Hemoglobin ? 9 g/dL; Erythropoietin and transfusion support is permitted provided treatments are not required more than every 8 weeks. Hemoglobin must be stable above or equal to 9 g/dL for at least 2 weeks prior to day 1of study drug without blood transfusion to maintain hemoglobin level.
  7. Adequate liver function as shown by:

    1. serum bilirubin ? 1.5x ULN
    2. PT/PTT/INR ? 1.5x ULN
    3. ALT and AST ? 2.5x ULN
  8. Adequate renal function: creatinine clearance (estimated) ? 50 cc/min by Cockroft Gault or 24 hour urine (see Appendix 6).
  9. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days from day 1 of study drug; both men and women must be willing to use two methods of contraception, one of them being a barrier method during the study and for 6 months after last study drug administration.
  10. Signed informed consent.
  11. Presence of an archived tumor sample (no size requirements).

Exclusion Criteria:

  1. Prior regorafenib use with disease progression (expanded cohort only).
  2. Prior failure to tolerate regorafenib at 120 mg/day.
  3. Patients currently receiving anticancer therapies or who have received anticancer therapies within 28 days from day 1 of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.)
  4. Patients who:

    1. Have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug,
    2. Have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or
    3. Are anticipated to require major surgery during the course of the study.
  5. Patients who have exhibited hypersensitivity reactions to regorafenib and/or a structural compound, biological agent, or formulation (eg sorafenib).
  6. Grade 3-4 AE associated with prior anti-VEGF therapy. Grade 3 hypertension that was readily managed will be permitted.
  7. History of grade 3 or higher hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins. Hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator.
  8. Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent with the following exceptions:

    1. Intermittent steroids (not to exceed 4 mg every day) may be used on an as-needed basis (e.g. treatment for chemotherapy-related nausea, anorexia and fatigue.)
    2. Patients on physiologic replacement doses of steroids due to adrenal insufficiency for any reason may remain on these medications.
    3. Topical, inhaled or intra-articular corticosteroids
  9. Active brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. Treated, asymptomatic metastases are permitted provided the patient has been off steroids for at least 1 month prior to day 1 of study drug.
  10. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or O2 saturation <90% by pulse oximetry after a 2 minute walk or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia.
  11. Presence of poorly controlled atrial fibrillation (ventricular heart rate >100 bpm)
  12. Previous history of CVA, TIA, angina pectoris, acute MI or history of recent re-perfusion procedures (e.g. PTCA), pulmonary embolus or untreated deep vein thrombosis (DVT) within 6 months from day 1 of study drug. NOTE: Subjects with recent DVT who have been therapeutically anti-coagulated for at least 6 weeks are eligible.
  13. Known significant or active CAD or PVD or CVD defined as abnormal stress test, symptoms, or requiring medication for the prevention of symptoms.
  14. Congestive heart failure (New York Heart Association (NYHA classification, see Appendix 4 functional classification III-IV).
  15. Proteinuria at screening demonstrated by urine analysis (UA) > 1+ and 24 hour urine protein ? 1 gram/24 hours.
  16. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study as so judged by the treating physician. Examples include but are not limited to:

    1. Severely impaired lung function (e.g. use of home O2, history of Idiopathic Lung Disease (ILD), any evidence of ILD on scan.
    2. Active (acute or chronic) severe infections requiring treatment with I.V. antibiotics.
    3. Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
    4. Poorly controlled hypertension [defined as systolic blood pressure (SBP of >140 mmHg or diastolic blood pressure (DBP) of >90 mmHg] NOTE: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals. At least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement. These three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure. The mean SBP/DBP ratio must be <140/90 mmHg in order for a subject to be eligible for the study.
  17. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral medications (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
  18. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1 of study drug
  19. History of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per episode) or other significant spontaneous bleeding event within 1 month prior to day 1 of study drug or at any time on a prior VEGF inhibitor.
  20. History of abdominal fistula or gastrointestinal perforation at any point within 6 months prior to day 1 of study drug, unless surgically repaired.
  21. Active peptic ulcer disease, inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding.
  22. Use or need for full dose anticoagulation other than low molecular weight heparin and Factor Xa inhibitors (e.g. Lovenox, Fondaparinux) and no other bleeding risk.
  23. Serious, non-healing wound, active ulcer, or untreated bone fracture as judged by treating physician.
  24. Active bleeding diathesis.
  25. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage.
  26. Known history of HIV or Hepatitis B or C seropositivity.
  27. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. Two acceptable forms of contraceptives must be continued throughout the trial by either sex and for 2 months (60 days) following last dose of either drug. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to day 1 of study drug).
  28. Concomitant use of CYP3A4 strong inducers and strong inhibitors. (See Appendix 7).
  29. Corrected QTc interval > 500 msec. If QTc interval is > 500 msec, then 2 additional ECGs should be obtained over a brief period of time (e.g., within 15-20 minutes) to confirm the abnormality. The average QTc interval will be determined from the 3 ECG tracings by manual evaluation and will be used to determine if the subject will be excluded from the study. The same method of QTc determination must be used throughout the subject's participation in the trial.
  30. History of Osler-Weber-Rendu syndrome or Hereditary Hemorrhagic Telangiectasia
  31. Patients unwilling to or unable to comply with the protocol.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02116894
Other Study ID Numbers  ICMJE Pro00051541
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Jeffrey Clarke, Duke University
Study Sponsor  ICMJE Duke University
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Herbert Hurwitz, MDDuke University
PRS Account Duke University
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP